Blue Dream #8
A numbered phenotype cut of Blue Dream with limited verifiable provenance and no chemistry meaningfully distinct from its parent.
Blue Dream #8 is best understood as a pheno-hunted selection of Blue Dream sold by various nurseries and seedbanks. There is no authoritative registry that defines what 'pheno #8' means — different vendors number their cuts differently. Assume its effects and chemistry sit inside the normal Blue Dream range: myrcene- or pinene-forward, THC-dominant, sativa-leaning in reported effect. Anyone promising you a specific, reproducible experience from a numbered pheno without lab data is selling a story, not a strain.
Overview
Blue Dream #8 is one of several numbered selections circulating under the Blue Dream name. 'Pheno numbers' are internal labels breeders use during pheno-hunting — the process of germinating many seeds from the same cross and picking standout individuals. Numbers are not standardized across breeders, so 'Blue Dream #8' from one seed company has no guaranteed relationship to '#8' from another Strong evidence.
The parent strain, Blue Dream, is widely reported to be a cross of Blueberry and Haze and became one of the best-selling cultivars in legal U.S. markets in the 2010s [1][2]. Blue Dream #8 inherits that commercial context: the name sells, the specifics rarely check out.
Chemistry
There is no peer-reviewed chemotyping study specific to a cut labeled 'Blue Dream #8.' What we can say comes from aggregated lab data on Blue Dream samples generally.
Cannabinoids. Blue Dream samples in U.S. testing databases typically fall in the 17–24% THC range with negligible CBD (<1%) [3] Weak / limited. CBG and minor cannabinoids sit at low single-digit percentages at most.
Terpenes. Chemotype work on Blue Dream and related 'Haze' descendants shows terpene profiles are variable but commonly myrcene-dominant, sometimes with elevated α-pinene, β-caryophyllene, and terpinolene [4] Weak / limited. The old marketing claim that 'myrcene above 0.5% makes a strain indica' is folklore with no controlled human evidence behind it [5] Disputed.
Because phenotype selections drift over time through cloning and re-selection, chemistry from a specific '#8' cut can only be trusted when it comes with a batch-specific certificate of analysis.
Reported effects
No clinical trial has ever tested Blue Dream, let alone a numbered phenotype of it. Effect descriptions come from user reports on commercial menus and review sites, which are subject to placebo, expectancy, and marketing effects [6] Anecdote.
Commonly reported effects for the Blue Dream family:
- Euphoric, talkative onset
- Mild body relaxation without heavy sedation
- Dry mouth and dry eyes (typical of most THC-dominant flower)
There is no reliable evidence that a #8 phenotype produces effects distinguishable from other Blue Dream cuts in a blinded setting. The industry-standard claim that indica vs. sativa vs. hybrid labels predict effects is not supported by chemotyping research [7] Strong evidence.
Lineage (disputed)
Blue Dream's lineage is popularly listed as Blueberry × Haze, with the original selection often credited to Santa Cruz growers in the mid-2000s. The specific Blueberry and Haze cuts used, and the identity of the original breeder, are not conclusively documented in any primary source [1] Disputed.
For Blue Dream #8 specifically:
- No breeder has published a verifiable origin story with dates, seed lot numbers, or genetic testing tying '#8' to a defined mother plant.
- Multiple seedbanks and clone-only vendors sell 'Blue Dream #8' independently of each other.
- Without genotyping (e.g., via services like Phylos or Medicinal Genomics), there is no way to confirm two '#8' cuts are the same plant [8] Weak / limited.
Treat any lineage chart for this strain as marketing until a verifiable genetic report is attached.
Cultivation basics
Grower reports for Blue Dream selections, including numbered phenos, are broadly consistent Anecdote:
- Flowering time: ~63–70 days indoors.
- Structure: Tall, stretchy, Haze-influenced. Responds well to topping, LST, and SCROG to manage canopy.
- Yield: Moderate to high indoors; vigorous outdoors in Mediterranean-type climates.
- Common issues: Susceptible to powdery mildew in humid environments; watch VPD during late flower.
- Nutrients: Handles standard feeding schedules; not notably heavy or light feeding compared to other hybrids.
None of this is unique to '#8.' If you're buying seeds or clones, ask the vendor for a batch COA and, ideally, a genotype report before assuming you're getting anything specific.
Marketing vs. reality
What the name promises: a special, elite cut of Blue Dream with distinctive effects.
What the evidence supports:
- Blue Dream is a real, widely-grown cultivar family with meaningful commercial history [2].
- 'Phenotype numbers' are internal breeder shorthand, not a standardized designation Strong evidence.
- No published chemotyping or clinical data distinguishes '#8' from other Blue Dream cuts No data.
- Effect predictions from strain names generally do not survive blinded testing [7] Strong evidence.
If a #8 cut you tried felt great, that's a legitimate personal data point. It's not evidence the number on the tag caused the experience.
Sources
- Reported Halperin, A. (2019). 'How Blue Dream, the pot strain that fueled the legal weed industry, lost its buzz.' The Washington Post.
- Reported Leafly Staff. Blue Dream strain data and market share reporting. Leafly.
- Peer-reviewed Jikomes, N., & Zoorob, M. (2018). The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports, 8, 4519.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
- Peer-reviewed Gilman, J. M., et al. (2022). Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults: A randomized clinical trial. JAMA Network Open, 5(3), e222106.
- Peer-reviewed Watts, S., McElroy, M., Migicovsky, Z., Maassen, H., van Velzen, R., & Myles, S. (2021). Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants, 7, 1330–1334.
- Peer-reviewed Sawler, J., Stout, J. M., Gardner, K. M., Hudson, D., Vidmar, J., Butler, L., Page, J. E., & Myles, S. (2015). The genetic structure of marijuana and hemp. PLoS ONE, 10(8), e0133292.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Blue Dream — California's most-sold sativa-dominant hybrid, famous for balanced effects, easy growing,...
- Haze — The long-flowering sativa landrace hybrid from 1970s California that became the genetic ba...